Short-term therapy with high dose atorvastatin in patients with coronary artery
disease can reduce inflammatory process.
Author(s): Nesar Hossein V, Yosef Nejad K, Abdollahian F.
Affiliation(s): Department of Internal Cardiology, Fatemeh Zahra Hospital of Sari, Mazandaran
University of Medical Sciences, Mazandaran, Iran. vida196180@yahoo.com
Publication date & source: 2010, Acta Med Iran. , 48(4):218-21
Coronary heart disease is the leading cause of death and disability in adults.
The association between acute coronary syndrome (ACS) and elevated serum high
sensitivity c-reactive protein (hsCRP) suggests that chronic inflammation of the
coronary arterial wall may play an important role. A number of drugs used in the
treatment of cardiovascular disease reduce serum CRP. It* is therefore possible
that reduced inflammation contributes to the beneficial effects of these
medications. This was a double blind randomized clinical trial on 52 patients
were admitted because of ACS at the Mazandaran Heart Center, Iran in 2007. The
patients were divided to three randomized groups which received 20, 40, 80* mg
Atorvastatin daily for 6 months. At the time of study enrollment and 1, 3 and 6
months after initiation hsCRP were measured. 1 and 3 month after 20mg
atorvastatin therapy the median serum concentration of hsCRP did not decrease
significantly, but at the end of 6th month it was* significant difference. At 40
mg dosage from 3rd month to 6th month versus 1st month to 3rd month it was
significant decrease, at the end of 1st month and 3rd month it was not
significant. At 80 mg dose at the end of 1st month it was not significant but at
the* end of 3rd month and end of 6th month it was significant. Intensive
lipid-lowering therapy with high-dose atorvastatin therapy relative to moderate
lipid-lowering therapy with low-dose atorvastatin reduces hsCRP better. We found
that treatment with greater dose of atorvastatin might decrease greater in plasma
level of hsCRP.
|